mlln
Navigation
Daily
Weekly
Monthly
Sector
Rank
Portfolio
Tools
Watchlist
My Portfolio
Mlln
About
Methodology
Score Criteria
Privacy
Upgrade to Pro
JD
James D.
Guest
Assets›Asset Details
E

EBS DCA Backtest — Dollar Cost Averaging Results

Emergent BioSolutions Inc. · Healthcare
Opportunity
DCA Score
74
Updated Oct 11, 2026

EBS DCA Results: Key Findings

Investing $100 per week into Emergent BioSolutions Inc. (EBS) using Enhanced DCA over the past 5 years resulted in a total investment of $68,348, growing to a current value of $82,222 — a return of 20%.

Standard dollar cost averaging over the same period returned 3%, making Enhanced DCA +18% more effective with a lower average entry price of $6 versus standard DCA's $7.

EBS DCA backtest results: standard vs enhanced
PeriodStandard DCAEnhanced DCAAlpha
1-Year-16%-3%+13%
3-Year36%92%+56%
5-Year3%20%+18%
Pro subscribers only

Alpha you missed while unsubscribed

Our Pro members bought these signals. Here's what the returns look like — and what was left on the table.

You weren't subscribed
Major Weekly Buy Signal
Signal issued Aug 17, 2026 when our algorithm told users to buy ↗ $600
+58.2%
return to date
Current value of $600 position
$949
You weren't subscribed
Major Monthly Buy Signal
Signal issued Aug 3, 2026 when our algorithm told users to buy ↗ $2,523
-5.4%
return to date
Current value of $2,523 position
$2,387
Live Signal & Allocation %
Weekly Buy
As of Oct 9, 2026 close
0%
No buy at this reading
Next signal on or after Oct 12, 2026
Monthly Buy
As of Oct 9, 2026 close
0%
No buy at this reading
Next signal on or after Nov 2, 2026
Signals like these fire across 1,958 assets
Emergent BioSolutions Inc. DCA Calculator
Weekly and Monthly DCA Calculator
Frequency
Amount
$100
/week
1 Year
+12.7% alpha
Standard
Invested
$0
Value
$0
Return
-16.1%
Enhanced
Invested
$0
Value
$0
Return
-3.4%
24 targeted purchases · avg entry $7
3 Years
+55.6% alpha
Standard
Invested
$0
Value
$0
Return
36.4%
Enhanced
Invested
$0
Value
$0
Return
92.0%
72 targeted purchases · avg entry $4
5 Years
+17.6% alpha
Standard
Invested
$0
Value
$0
Return
2.7%
Enhanced
Invested
$0
Value
$0
Return
20.3%
146 targeted purchases · avg entry $6
Alpha Advantage · 5Y Enhanced DCA
+17.6%
Enhanced DCA achieved higher returns on the capital it deployed — with a lower average entry price than standard DCA
Avg entry$6 vs $7
5Y return20.3% vs 2.7%
Ending value ahead+$55,413
Backtest analysis

Dollar cost averaging into EBS — backtest results

Investing $100/week into EBS (Emergent BioSolutions Inc.) using standard dollar cost averaging over the past 5 years would have resulted in a total investment of $26,100 across 261 purchases, growing to a current value of $26,810 — a return of 3%.

Using Enhanced DCA — which automatically buys more when multiple signals agree conditions are right, and holds back when they don't — See the full methodology. The same $100/week base deployed $68,348 across 146 targeted purchases, growing to $82,222. That's a return of 20% — +18% more than standard DCA, with a lower average entry price of $6 vs $7.

Over the same 5-year period, standard weekly DCA into the S&P 500 (SPY) returned approximately 53%, so EBS's 20% Enhanced DCA return was below the index over the same period.

1-year weekly DCA results
Standard: $5,200 → $4,365 · -16%
Enhanced: $9,886 → $9,552 · -3%
3-year weekly DCA results
Standard: $15,700 → $21,413 · 36%
Enhanced: $31,214 → $59,925 · 92%
5-year weekly DCA results
Standard: $26,100 → $26,810 · 3%
Enhanced: $68,348 → $82,222 · 20%

Buying the dips for Emergent BioSolutions Inc.

i
Weekly buy signals for EBS. Larger markers are larger purchases, up to 6 times the base amount.
Frequently asked questions
How Enhanced DCA works
Multiple signals, one smarter decision
The buy multiplier is built from several inputs on the signal date: momentum (RSI), distance from the long term average, how far price has fallen from its yearly high, trend direction, and market fear (VIX). Each one scales the buy, so a week with a steep drawdown and elevated fear can produce a much larger buy.
Only what was known at the time
Every historical signal is computed from the prices available on its own date and nothing later, so the backtest cannot benefit from hindsight. Buys fill at the next day's open.
Same budget, working harder
Standard DCA buys the same amount every period. Enhanced DCA buys more when the model sees a dip and skips periods when it does not, so capital is concentrated at lower prices. The result can be a lower or higher total spend than standard DCA, and both are shown above.
Risk Disclosure: Past backtest performance does not guarantee future results. Dollar cost averaging into Emergent BioSolutions Inc. (EBS) involves investment risk, including potential loss of principal. EBS is a Healthcare stock whose price can fall as well as rise. This analysis is for informational purposes only and does not constitute financial advice. Always consult a qualified financial advisor before investing.
Explore other assets
Similar DCA backtests
Prices as of 9 October 2026 close · Backtest rebuilt 11 October 2026